Corpus overview


MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


SARS-CoV-2 Proteins
    displaying 1 - 1 records in total 1
    records per page

    Predictors of Mortality in COVID-19 MESHD Patients at Kinshasa Medical Center and A Survival Analysis: A Retrospective Cohort Study

    Authors: Yannick MAYAMBA NLANDU; Danny Mafuta; Junior Sakaji; Melinda Brecknell; Yannick Engole; Jessy Abatha; Jean-Robert Nkumu; Aliocha Nkodila; Marie-France Mboliassa; Olivier Tuyinama; Dauphin Bena; Yves Mboloko; Patrick Kobo; Patrick Boloko; Joseph Tshangu; Philippe Azika; Jean-Pierre Kanku; Pally Mafuta; Magloire Atantama; Jean-Michel Mavungu; Rosita Kitenge; Asma Sehli; Karel Van Eckout; Cathy Mukuku; Léo Bergeret; David Benchetritt; Golan Kalifa; Ahmed Rodolphe; Justine Bukabau

    doi:10.21203/ Date: 2021-01-23 Source: ResearchSquare

    BackgroundDespite it being a global pandemic, there is little research examining the clinical features of severe COVID-19 MESHD in sub-Saharan Africa. This study aims to identify predictors of mortality in COVID-19 MESHD patients in an African setting.MethodsIn this retrospective, observational, cohort study carried out at the Kinshasa Medical Centre (KMC) between March 10 HGNC, 2020 and July 10, 2020, we included all adult inpatients (≥18 years old) with a laboratory diagnosis by PCR of COVID-19 MESHD. The end point of the study was survival to discharge (time-to-death).The study population was dichotomized into survivors and non-survivors group. Kaplan-Meier plot was used for survival analyses. The Log-Rank test was employed to compare the survival curves. Predictors of mortality were identified by Cox regression models. The significance level of P value was set at 0.05.Results106 patients (mean age 55.6±13.2 years old, 80.2% were male), were included in this study, of whom 34 (32 %) died during their hospitalisation. The main Complications of the patients included ARDS in 59/66 (89.4%) patients, coagulopathy MESHD in 35/93 (37.6%) patients, acute cardiac injury MESHD in 24/98 (24.5%) patients, AKI in 15/74 (20.3%) patients and secondary infection MESHD in 12/81 (14.8%) patients. The independent predictors of mortality were found to be age ≥ 65 years [aHR 2.49; 95% CI: 1.53-5.69], AKI stage 3 [aHR 2.51; 95% CI: 1.33-6.80], proteinuria MESHD [aHR 2.60; 95% CI: 1.40-6.42], CRP HGNC >150 mg/L [aHR 2.75; 95% CI: 1.29-3.68] and procalcitonin (PCT) > 0.5 ng/ml [aHR 3.20; 95% CI: 1.70-7.49].The median survival time of the entire group was 12 days. The cumulative survival rate of COVID-19 MESHD patients was 86.9%, 65.0% and 19.9% respectively at 5, 10 and 20 days. Levels of creatinine (p= 0.012), were clearly elevated in non-survivors compared with survivors throughout the clinical course and increased deterioration.ConclusionThe results from this study demonstrated that an advanced age, proteinuria MESHD, AKI and raised CRP HGNC and PCT offered a worse prognosis in COVID-19 MESHD patients. In addition, serum levels of creatinine significantly rose during admission in the non-survivor group compared with those who survived to discharge.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.